

Helena J Tutill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7170509/publications.pdf>

Version: 2024-02-01

8
papers

154
citations

1307594

7
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

189
citing authors

#	ARTICLE	IF	CITATIONS
1	NIX-mediated mitophagy regulate metabolic reprogramming in phagocytic cells during mycobacterial infection. <i>Tuberculosis</i> , 2021, 126, 102046.	1.9	16
2	Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17 β -Hydroxysteroid Dehydrogenase Type 3. <i>Molecules</i> , 2021, 26, 7166.	3.8	1
3	Kallikrein-Mediated Cytokeratin 10 Degradation Is Required for Varicella Zoster Virus Propagation in Skin. <i>Journal of Investigative Dermatology</i> , 2020, 140, 774-784.e11.	0.7	13
4	Low Prevalence of Conjunctival Infection with <i>Chlamydia trachomatis</i> in a Treatment-Na \tilde{v} e Trachoma-Endemic Region of the Solomon Islands. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004863.	3.0	42
5	STX2171, a 17 β -hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. <i>Endocrine-Related Cancer</i> , 2013, 20, 53-64.	3.1	17
6	The design of novel 17 β -hydroxysteroid dehydrogenase type 3 inhibitors. <i>Molecular and Cellular Endocrinology</i> , 2009, 301, 259-265.	3.2	26
7	Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17 β -hydroxysteroid dehydrogenase Type 3. <i>Molecular and Cellular Endocrinology</i> , 2009, 301, 251-258.	3.2	16
8	Novel, potent inhibitors of 17 β -hydroxysteroid dehydrogenase type 1. <i>Molecular and Cellular Endocrinology</i> , 2006, 248, 204-207.	3.2	23